nabumetone has been researched along with Peptic Ulcer in 14 studies
Nabumetone: A butanone non-steroidal anti-inflammatory drug and cyclooxygenase-2 (COX2) inhibitor that is used in the management of pain associated with OSTEOARTHRITIS and RHEUMATOID ARTHRITIS.
nabumetone : A methyl ketone that is 2-butanone in which one of the methyl hydrogens at position 4 is replaced by a 6-methoxy-2-naphthyl group. A prodrug that is converted to the active metabolite, 6-methoxy-2-naphthylacetic acid, following oral administration. It is shown to have a slightly lower risk of gastrointestinal side effects than most other non-steroidal anti-inflammatory drugs.
Peptic Ulcer: Ulcer that occurs in the regions of the GASTROINTESTINAL TRACT which come into contact with GASTRIC JUICE containing PEPSIN and GASTRIC ACID. It occurs when there are defects in the MUCOSA barrier. The common forms of peptic ulcers are associated with HELICOBACTER PYLORI and the consumption of nonsteroidal anti-inflammatory drugs (NSAIDS).
| Excerpt | Relevance | Reference |
|---|---|---|
| ", Skokie, Illinois) administered twice daily with that of nabumetone 1500 mg administered once daily in 1203 patients with symptomatic osteoarthritis (OA) of the hip or knee." | 9.09 | Comparison of the upper gastrointestinal safety of Arthrotec 75 and nabumetone in osteoarthritis patients at high risk for developing nonsteroidal anti-inflammatory drug-induced gastrointestinal ulcers. ( Agrawal, NM; Ball, J; Bocanegra, TS; Caldwell, J; Dhadda, S; Hancock, L; Hurley, S; Kivitz, AJ; Weaver, AL, 1999) |
| "The results suggest that nabumetone was similar in efficacy by most criteria to diclofenac SR and piroxicam in relieving the symptoms of osteoarthritis; however, nabumetone's GI safety profile was generally superior to that of both comparator NSAIDs." | 9.09 | Safety and efficacy of nabumetone in osteoarthritis: emphasis on gastrointestinal safety. ( Palmer, RH; Scott, DL, 2000) |
| "To compare the efficacy and safety of nabumetone and diclofenac sodium in the treatment of patients with rheumatoid arthritis (RA)." | 9.09 | [Comparison of the efficacy and safety of nabumetone and diclofenac sodium in the treatment of patients with rheumatoid arthritis]. ( , 2001) |
| " Nabumetone (Relafen), a new NSAID for the treatment of rheumatoid arthritis (RA) and osteoarthritis (OA), may differ from the others." | 8.78 | Nabumetone: a new NSAID for rheumatoid arthritis and osteoarthritis. ( Roth, SH, 1992) |
| "To identify the unbiased differences in the risk of hospitalization with peptic ulcer disease (PUD) or gastrointestinal (GI) hemorrhage among populations using 4 nonsteroidal antiinflammatory drugs (NSAID): nabumetone, Arthrotec, diclofenac plus a cytoprotective agent dispensed separately (diclo+coRx), and naproxen." | 7.73 | Risk of hospitalization with peptic ulcer disease or gastrointestinal hemorrhage associated with nabumetone, Arthrotec, diclofenac, and naproxen in a population based cohort study. ( Ashworth, NL; Muhajarine, N; Peloso, PM; Stang, M, 2005) |
| ", Skokie, Illinois) administered twice daily with that of nabumetone 1500 mg administered once daily in 1203 patients with symptomatic osteoarthritis (OA) of the hip or knee." | 5.09 | Comparison of the upper gastrointestinal safety of Arthrotec 75 and nabumetone in osteoarthritis patients at high risk for developing nonsteroidal anti-inflammatory drug-induced gastrointestinal ulcers. ( Agrawal, NM; Ball, J; Bocanegra, TS; Caldwell, J; Dhadda, S; Hancock, L; Hurley, S; Kivitz, AJ; Weaver, AL, 1999) |
| "The results suggest that nabumetone was similar in efficacy by most criteria to diclofenac SR and piroxicam in relieving the symptoms of osteoarthritis; however, nabumetone's GI safety profile was generally superior to that of both comparator NSAIDs." | 5.09 | Safety and efficacy of nabumetone in osteoarthritis: emphasis on gastrointestinal safety. ( Palmer, RH; Scott, DL, 2000) |
| "To evaluate the efficacy and gastrointestinal safety of nabumetone and diclofenac in the treatment of elderly patients with osteoarthritis, participating in a 3-month efficacy trial." | 5.09 | Treatment of elderly patients with nabumetone or diclofenac: gastrointestinal safety profile. ( DeLapp, R; Kaine, J; Morgan , GJ; Palmer, R, 2001) |
| "To compare the efficacy and safety of nabumetone and diclofenac sodium in the treatment of patients with rheumatoid arthritis (RA)." | 5.09 | [Comparison of the efficacy and safety of nabumetone and diclofenac sodium in the treatment of patients with rheumatoid arthritis]. ( , 2001) |
| "The objective of this endoscopic, double-blind study was to evaluate the gastric tolerability of nabumetone, a novel nonsteroidal anti-inflammatory drug, compared with naproxen in patients with rheumatoid arthritis." | 5.08 | Gastroduodenal tolerability of nabumetone versus naproxen in the treatment of rheumatic patients. ( Bianchi Porro, G; Caruso, I; Imbesi, V; Montrone, F; Petrillo, M, 1995) |
| "To compare the gastrointestinal safety, ulcerogenic potential, and clinical efficacy over 5 years of nabumetone and naproxen therapy, in patients with rheumatoid arthritis (RA) or osteoarthritis (OA)." | 5.07 | A longterm endoscopic evaluation of patients with arthritis treated with nabumetone vs naproxen. ( Bennett, R; Caldron, P; Koepp, R; Mitchell, C; Roth, SH; Swenson, C, 1994) |
| " In an ongoing study of patients with osteo- or rheumatoid arthritis, currently in its fourth year, nabumetone has been shown to be relatively gastric sparing when compared with naproxen." | 5.06 | New understandings of NSAID gastropathy. ( Roth, SH, 1989) |
| "A total of 1,924 persons (rheumatoid arthritis, 835; osteoarthritis, 1,073; volunteers, 16) received nabumetone in United States clinical trials." | 5.06 | Safety evaluation of nabumetone in United States clinical trials. ( Brindley, DA; Jackson, RE; Mitchell, FN, 1987) |
| "Prespecified analysis of all 8 double-blind, randomized phase 2b/3 rofecoxib osteoarthritis trials conducted from December 1996 through March 1998, including one 6-week dose-ranging study, two 6-week efficacy studies vs ibuprofen and placebo, two 1-year efficacy studies vs diclofenac, two 6-month endoscopy studies vs ibuprofen and placebo, and one 6-week efficacy study vs nabumetone and placebo." | 4.80 | Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. ( Bolognese, JA; Harper, SE; Jensen, DM; Langman, MJ; Quan, H; Simon, TJ; Watson, DJ; Zhao, PL, 1999) |
| " Nabumetone (Relafen), a new NSAID for the treatment of rheumatoid arthritis (RA) and osteoarthritis (OA), may differ from the others." | 4.78 | Nabumetone: a new NSAID for rheumatoid arthritis and osteoarthritis. ( Roth, SH, 1992) |
| "To identify the unbiased differences in the risk of hospitalization with peptic ulcer disease (PUD) or gastrointestinal (GI) hemorrhage among populations using 4 nonsteroidal antiinflammatory drugs (NSAID): nabumetone, Arthrotec, diclofenac plus a cytoprotective agent dispensed separately (diclo+coRx), and naproxen." | 3.73 | Risk of hospitalization with peptic ulcer disease or gastrointestinal hemorrhage associated with nabumetone, Arthrotec, diclofenac, and naproxen in a population based cohort study. ( Ashworth, NL; Muhajarine, N; Peloso, PM; Stang, M, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (14.29) | 18.7374 |
| 1990's | 8 (57.14) | 18.2507 |
| 2000's | 4 (28.57) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ashworth, NL | 1 |
| Peloso, PM | 1 |
| Muhajarine, N | 1 |
| Stang, M | 1 |
| Bianchi Porro, G | 1 |
| Montrone, F | 1 |
| Petrillo, M | 1 |
| Caruso, I | 1 |
| Imbesi, V | 1 |
| Roth, SH | 5 |
| Bennett, R | 1 |
| Caldron, P | 1 |
| Mitchell, C | 1 |
| Swenson, C | 1 |
| Koepp, R | 1 |
| Tindall, EA | 1 |
| Jain, AK | 1 |
| McMahon, FG | 1 |
| April, PA | 1 |
| Bockow, BI | 1 |
| Cohen, SB | 1 |
| Fleischmann, RM | 1 |
| Lanza, FL | 1 |
| Agrawal, NM | 1 |
| Caldwell, J | 1 |
| Kivitz, AJ | 1 |
| Weaver, AL | 1 |
| Bocanegra, TS | 1 |
| Ball, J | 1 |
| Dhadda, S | 1 |
| Hurley, S | 1 |
| Hancock, L | 1 |
| Langman, MJ | 1 |
| Jensen, DM | 1 |
| Watson, DJ | 1 |
| Harper, SE | 1 |
| Zhao, PL | 1 |
| Quan, H | 1 |
| Bolognese, JA | 1 |
| Simon, TJ | 1 |
| Scott, DL | 1 |
| Palmer, RH | 1 |
| Morgan , GJ | 1 |
| Kaine, J | 1 |
| DeLapp, R | 1 |
| Palmer, R | 1 |
| Jackson, RE | 1 |
| Mitchell, FN | 1 |
| Brindley, DA | 1 |
4 reviews available for nabumetone and Peptic Ulcer
| Article | Year |
|---|---|
Gastrointestinal toxicity of newer NSAIDs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Butanones; Etodolac; Gastrointestinal Hemorrhage; Humans; N | 1993 |
Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs.
Topics: Adult; Aged; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Cyclooxyg | 1999 |
Nabumetone: a new NSAID for rheumatoid arthritis and osteoarthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Butanones; Humans; Nabumetone; Osteo | 1992 |
NSAID gastropathy. The central issue.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Butanones; Humans; Nabumetone; Naproxen; Peptic Ulcer | 1990 |
9 trials available for nabumetone and Peptic Ulcer
| Article | Year |
|---|---|
Gastroduodenal tolerability of nabumetone versus naproxen in the treatment of rheumatic patients.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Butanones; Double-Blind Method; Duod | 1995 |
A longterm endoscopic evaluation of patients with arthritis treated with nabumetone vs naproxen.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Butanones; Double-Blind Method | 1994 |
A controlled study comparing the effects of nabumetone, ibuprofen, and ibuprofen plus misoprostol on the upper gastrointestinal tract mucosa.
Topics: Aged; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Endoscopy, Digestive | 1993 |
Comparison of the upper gastrointestinal safety of Arthrotec 75 and nabumetone in osteoarthritis patients at high risk for developing nonsteroidal anti-inflammatory drug-induced gastrointestinal ulcers.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Diclofenac; Double-Blind Method; Dr | 1999 |
Safety and efficacy of nabumetone in osteoarthritis: emphasis on gastrointestinal safety.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Digestive System; Double-Blind Meth | 2000 |
Treatment of elderly patients with nabumetone or diclofenac: gastrointestinal safety profile.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Butanones; D | 2001 |
[Comparison of the efficacy and safety of nabumetone and diclofenac sodium in the treatment of patients with rheumatoid arthritis].
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Butanones; | 2001 |
New understandings of NSAID gastropathy.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Butanones; Clinical Trials as Topic | 1989 |
Safety evaluation of nabumetone in United States clinical trials.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Butanones; Clinical Tri | 1987 |
1 other study available for nabumetone and Peptic Ulcer
| Article | Year |
|---|---|
Risk of hospitalization with peptic ulcer disease or gastrointestinal hemorrhage associated with nabumetone, Arthrotec, diclofenac, and naproxen in a population based cohort study.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Cohort Studies; Databas | 2005 |